PTC Therapeutics reported $211.54M in Operating Expenses for its fiscal quarter ending in June of 2026.





Operating Expenses Change Date
Acadia Pharmaceuticals USD 270.57M 450K Sep/2026
Alnylam Pharmaceuticals USD 1.11B 52.78M Sep/2026
Amgen USD 5.69B 6B Sep/2026
BioCryst Pharmaceuticals USD -397.38M 517.17M Sep/2026
Biogen USD 2.32B 663.6M Sep/2026
BioMarin Pharmaceutical USD 819.04M 5.5B Sep/2026
Cytokinetics USD 214.64M 6.85M Sep/2026
Daiichi Sankyo JPY 483.8B 5.85B Sep/2026
Enanta Pharmaceuticals USD 126.59M 346.51M Dec/2025
Gilead Sciences USD 13.04B 9.09B Sep/2026
Incyte USD 5.64B 4.67B Sep/2026
Ionis Pharmaceuticals USD 373M 2.76M Sep/2026
Ironwood Pharmaceuticals USD 57.33M 8.63M Dec/2024
Karyopharm Therapeutics USD 61.83M 9.9M Mar/2026
Novartis USD 9.88B 325M Sep/2026
Pfizer USD 89B 3.81B Sep/2026
PTC Therapeutics USD 211.54M 15.12M Jun/2026
Puma Biotechnology USD 49.26M 3.2M Jun/2024
Roche Holding CHF 18.9B 2.12B Jun/2026
Sangamo BioSciences USD 33.87M 12.89M Jun/2024
Sarepta Therapeutics USD 390.39M 2.43M Sep/2026
TG Therapeutics USD 174.04M 44.62M Sep/2026
Ultragenyx Pharmaceutical USD 283M 6M Sep/2026
Vertex Pharmaceuticals USD 2.18B 118.2M Sep/2026
Xencor USD 87.82M 5.44M Jun/2026